Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

על הניסוי

The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.

צפו ב-NCT01225211 ב-ClinicalTrials.gov ←

קישורים קשורים